Form 4: Oncology Institute CEO Daniel Virnich Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Daniel Virnich, CEO of Oncology Institute, sold 20,388 shares of common stock on May 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On May 21, 2025, Daniel Virnich, the CEO of Oncology Institute, Inc. (TOI), sold 20,388 shares of the company's common stock.
- The sale was executed at a price of $2.675 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the transaction, Virnich directly owns 1,787,309 shares of Oncology Institute, Inc.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes on vested RSUs) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based awards like RSUs. This type of transaction is common and doesn't necessarily reflect a change in the executive's long-term outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of transaction: Daniel Virnich sold shares of Oncology Institute, Inc. |
| 05/22/2025 | Date of signature for the Form 4 filing. |
Keywords
Oncology Institute, TOI, Daniel Virnich, Form 4, SEC Filing, Executive Compensation, Restricted Stock Units, Tax Withholding, Share Sale, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.